NCT05762510View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

April 1, 2028

Study Completion Date

October 31, 2030

Conditions
Transfusion Dependent Beta-Thalassemia
Interventions
GENETIC

GMCN-508B (LentiRed)

LentiRed Drug Product is administered by intravenous infusion following myeloablative conditioning with busulfan.

Trial Locations (1)

530021

RECRUITING

The affiliated hospital of guangxi medical university, Nanning

Sponsors

Collaborators (1)

Genmedicn Biopharma Ltd.
All Listed Sponsors
collaborator

Genmedicn Biopharma Ltd.

UNKNOWN

lead

First Affiliated Hospital of Guangxi Medical University

OTHER